Unresectable Bladder Urothelial Carcinoma
4 clinical trials · Condition
◉ Watch Unresectable Bladder Urothelial Carcinoma
| Record | Firm | Date |
|---|---|---|
| Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer (NCT07667335) | Fred Hutchinson Cancer Center | 2026-12-01 |
| ARID1A and/or KDM6A Mutation and CXCL13 Expression (NCT04953104) | M.D. Anderson Cancer Center | 2021-09-21 |
| Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma (NCT03513952) | National Cancer Institute (NCI) | 2019-06-05 |
| Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer (NCT03237780) | National Cancer Institute (NCI) | 2018-07-20 |
Track Unresectable Bladder Urothelial Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.